Jessica zucman-rossi
  • E-mail :[email]
  • Phone : +33 1 53 72 51 66
  • Location : Paris, France
Last update 2015-04-03 10:06:08.69

Jessica zucman-rossi Professor in Oncology, MD, PhD

Course and current status

Professor of Medicine, University Paris Descartes-HEGP. Oncology department.

Director of the Inserm unit U1162: “Functional genomic of solid tumors”, Paris France

Chairman of the scientific committee CSS2 at Inserm “Genetic, Epigenetic and Cancer”

Education

1990    Doctor in Medicine, University Paris 7, France

1994    Specialization in Internal Medicine (AIHP)

1994    PhD in life science, Fundamental Basis of Oncogenesis, University Paris 7

1998    Agreement for Research Direction (HDR), University Paris 7

Postgraduate Education

1987-1994       Resident in Internal Medicine, Hopitaux de Paris, in alternation with PhD.

1994‑1996       Post-doctoral research Fellow in Genetic-Oncology, Institut Curie (Director: Gilles Thomas)

Academic Appointments

2008-present  Director of the Inserm U1162 (ex U674) laboratory « Functional genomic of solid tumors »

1996‑2007       Staff Inserm scientist at unit U434 then U674, group Leader

Editorial and Review Activities

  • Associate editor Journal of Hepatology (2009-2014), Senior editor (2014-2019)
  • Editorial board of Hepatology (2009-2011), Journal of Hepatology (2005-2008), Word Journal of Gastroenterology (2005-2007), GCB (2010-)
  • Ad Hoc Journal Reviewer for >20 different International Journals including Nature, Nature Genet, Nature Medicine, Cancer cell, Gastroenterology, hepatology…
  • Scientific reviewer for research proposal for ERC, AERES, AFEF, AICR, AIRC, ANR, ANRS, BMRC Singapour, CNS, CNRS, Hong Kong, Inca, Inserm, ISF, KU Leuven, LNCC, Paris university, Swiss National Science Foundation, SINOFI.

Member of scientific committees

Institut National du Cancer (Inca) chairman of the « Translational Research proposal 2009 », chairman of the IGR Foundation scientific committee. Member of several scientific boards: Ligue National de recherche sur le Cancer (LNCC), Association pour la recherche sur le Cancer (ARC, CN2), Agence Nationale pour la recherche sur le Sida et les hépatite virales (ANRS, CSS4), Institut Universitaire d’Hématologie (IUH), Inserm scientific committees (CT1, 2003-2007; AVENIR 2007-2010).

Member of the governing board of ILCA (International Liver Cancer Association); co-organizer of the liver FASEB meeting (2012), Liver tumor AACR symposium (2013), EASL HCC conference (2014)

Scientific summary

Hepatocellular carcinoma (HCC) is one of the leading causes of death by cancer worldwide. It is mainly developed on cirrhosis due to chronic hepatitis B and C, metabolic and alcoholic liver diseases in western countries. In contrast, hepatocellular adenomas are rare benign liver tumors frequently developed in women after oral contraception. Recent advances in molecular classification and dissection of genetic and epigenetic drivers have increased our knowledge of the molecular diversity of benign and malignant liver tumors. Using genomic approaches, we identified several new oncogenes and tumor suppressor genes and we described a molecular classification of hepatocellular adenomas that is used in clinical routine. Recently, using sequencing, we identified TERT promoter mutations activating telomerase as the most important mechanism of malignant transformation of both adenoma in carcinoma and of cirrhotic nodules in carcinoma. We also found new etiological factors predisposing to liver tumor development and new drug targets.

Image d’exemple